# Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer

> **NCT01034189** · PHASE2 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 62 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT01034189
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-10
- **Primary completion:** 2010-12
- **Final completion:** 2012-06
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2009-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01034189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01034189, "Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT01034189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*